National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Darolutamide is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.

NCPE Assessment Process Complete
Rapid Review commissioned 27/04/2020
Rapid Review completed 25/05/2020
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of darolutamide compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 27/05/2020
Current status Pre-submission consultation scheduled